Pharmaceutical Manufacturers NAICS 3254

Jul 2, 2025 - AI Security may Be Inadequate At Many Organizations

• Only 17% of pharmaceutical industry organizations surveyed by data security firm Kiteworks have implemented automated controls to prevent sensitive data from leaking through AI tools. The remaining 83% depend on human-centered approaches: Forty percent rely on employee training sessions and periodic audits, essentially hoping staff will remember and follow the rules when working under pressure. Another 20% send warning emails about AI usage but never verify compliance. Ten percent have only issued guidelines, while 13% have no policies whatsoever. These organizations — including many contract development and manufacturing organizations — operate without basic technical safeguards while their employees paste molecular structures, clinical trial results, and patient records into ChatGPT, Claude, Perplexity, and other AI platforms, according to Kiteworks.
• President Trump said during a meeting with pharmaceutical and technology industry executives that companies which move their operations to plants in the US would face no tariffs, according to The Guardian. He also suggested that companies would have the time needed to repatriate some manufacturing with new or expanded operations in the US before they would face a “tariff wall”. President Trump paused his “reciprocal” tariffs for 90 days after they prompted a sell-off of US government bonds in April but he has repeatedly threatened to carry through with sectoral tariffs on the pharmaceutical industry.

• Annual out-of-pocket costs for the Medicare Part D drug benefit will be capped at $2,000 in 2025, according to the Centers for Medicare & Medicaid Services (CMS). Many insurers are increasing premiums for their stand-alone drug plan offerings, however, according to health policy research firm KFF. Some major plan sponsors, including Aetna and UnitedHealthcare, are also reducing their stand-alone prescription drug plan offerings, and overall, there will be fewer prescription drug plans in 2025 than in 2024 – 524 plans nationwide, down from 709 in 2024.
• Pharmaceutical manufacturing industry employment and wages for nonsupervisory employees increased slightly during the first five months of 2025, according to the US Bureau of Labor Statistics (BLS). Pharmaceutical manufacturers raised their prices slightly during the first half of 2025, according to the BLS.